Keloid injection prescription
Reading File
Keloid injection typically uses intralesional corticosteroids, primarily triamcinolone acetonide, to flatten and soften the scar. Let me pull up the detailed textbook content and recent evidence.
Searching sources...
Finding Sources
Searching PubMed
keloid intralesional corticosteroid injection treatment
Good results. Let me read the detailed textbook sections now.
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to give a detailed prescription guide. Here is the full answer:
Keloid Intralesional Injection - Prescription Guide
First-Line Agent: Triamcinolone Acetonide (TA)
Standard Prescription
Drug: Triamcinolone acetonide suspension (Kenalog)
| Parameter | Detail |
|---|---|
| Concentration | Start: 10 mg/mL; increase to 20-40 mg/mL if needed |
| Dilution | Dilute 1:3 with normal saline or 1% lidocaine (single-dose vials) → gives 2.5 mg/mL starting solution |
| Syringe | 1 mL tuberculin Luer-Lok syringe |
| Needle | 27- or 30-gauge needle |
| Technique | Inject intralesionally (into the substance of the scar), bevel down; advance through the lesion while injecting; keep injection within the lesion margins |
| Endpoint | Scar should blanch slightly during injection |
| Frequency | Every 4-8 weeks (typically every 6 weeks) |
| Duration | Repeat as needed; reassess after 3-6 sessions |
Locked (Luer-Lok) syringes are preferred to prevent needle disengagement under high injection pressure in dense keloids.
Concentration Titration
- Small, soft, or early keloids: Dilute to 2.5 mg/mL (1:3 dilution with saline or 1% lidocaine)
- Moderate/refractory keloids: 10 mg/mL undiluted or 1:2 with lidocaine
- Dense/old keloids: 40 mg/mL undiluted (Kenalog-40)
- Fitzpatrick's Dermatology recommends starting at 10 mg/mL and titrating up to 40 mg/mL as needed
A common error is being too aggressive too early - go slowly to avoid atrophy.
Pre-injection: Anesthesia
- Inject 1% lidocaine around (not into) the lesion using a 27-31 gauge needle before the TA injection
- Alternatively, mix 1% lidocaine directly into the TA solution for patient comfort
Optional: Cryotherapy Pre-treatment
Before the TA injection, apply liquid nitrogen spray for a 3-5 second burst to the keloid:
- Creates tissue edema, softening the lesion
- Allows better steroid dispersal and penetration
- Reduces injection pressure needed and decreases pain
- Wait 20-60 minutes for edema to develop before injecting
Combination Regimens (for Refractory/Large Keloids)
TA + 5-Fluorouracil (5-FU)
A 2024 meta-analysis (PMID 37337341) showed combination TA + 5-FU is superior to either agent alone.
| Agent | Dose | Notes |
|---|---|---|
| Triamcinolone acetonide | 10-40 mg/mL | As above |
| 5-Fluorouracil | 50 mg/mL | Mix with TA; typical ratio 9:1 (5-FU:TA) |
- 5-FU mechanism: inhibits fibroblast proliferation by blocking DNA synthesis; decreases TGF-β-induced collagen type I expression
- Response rate: up to 95% with 5-FU alone; 75%+ reduction in 40% of cases
- Side effects of 5-FU: pain, hyperpigmentation, ulceration (less frequent with combination)
TA + Verapamil
- Verapamil (calcium channel blocker) decreases IL-6, VEGF, and inhibits keloid fibroblast growth
- Used as an alternative combination agent
Triple Therapy: 5-FU + TA + Pulsed Dye Laser (PDL)
- Average flattening ~79% with maximal triple therapy vs ~50% with TA monotherapy
- PDL sessions coordinated with injection visits
Perioperative Protocol (Post-excision Prophylaxis)
For surgically excised keloids, to prevent recurrence:
- 3 months before surgery: TA injection 2.5-5.0 mg/mL into the keloid-normal skin interface
- 6 weeks before surgery: Repeat TA injection
- Day of surgery: TA mixed with local anesthetic at time of excision
- 4 weeks post-op: Follow-up, inject early if recurrence signs appear
- 8 weeks post-op: Follow-up; continue injections every 3 months for 1-2 years
Post-excision recurrence rate with steroid injection is significantly lower than excision alone (which has >50% recurrence).
Other Intralesional Agents
| Agent | Notes |
|---|---|
| Bleomycin | 66-84% show >75% flattening; risk of hyperpigmentation (esp. darker skin) and local atrophy; no systemic toxicity at keloid doses |
| Interferon-α2b | Less evidence; not clearly superior to TA post-excision |
| Etanercept | Intralesional; some efficacy shown |
Side Effects to Counsel
- Hypopigmentation - most common; often improves over time; reduced by lower concentrations and dilution
- Perilesional skin atrophy
- Perilymphatic linear atrophy (spread along lymphatics from injection site)
- Telangiectasia
- Hyperpigmentation (more with 5-FU)
- Systemic corticosteroid effects - rare; possible with repeated high-dose injections
Key Points
- Intralesional TA flattens and softens keloids and stops itching reliably, but does not narrow the scar - width is not reduced
- Young, small keloids respond better than old, large ones
- Keloids >1-1.5 cm diameter generally resolve more slowly and incompletely
- Hyperpigmentation typically persists even with successful treatment
- Silicone gel sheeting can be used adjunctively between injection sessions
Sources: Andrews' Diseases of the Skin (Clinical Dermatology), p. 449 | Pfenninger and Fowler's Procedures for Primary Care, p. 278 | Fitzpatrick's Dermatology, p. 1138 | Cummings Otolaryngology, p. 3965
Recent evidence (PMID 41860092 - 2026 network meta-analysis) continues to support combination intralesional therapies as superior to TA monotherapy for keloid treatment.
This is a shared conversation. Sign in to Orris to start your own chat.